Aspireo Pharmaceuticals Ltd is a biopharmaceutical company focused on the development of a novel somatostatin analog (SSA) for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushing’s disease and diabetic retinopathy.
Aspireo’s sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide.
During extensive preclinical testing, Somatoprim has demonstrated a unique receptor binding and pharmacological profile which is significantly differentiated from SSAs that are currently marketed or in clinical development. In particular, Somatoprim has demonstrated an improved side effect profile with minimal adverse effects on the gastrointestinal tract and metabolic control. Furthermore, assessment of growth hormone secretion in cultured human somatotroph adenoma tissue treated with Somatoprim suggests that it has the potential to significantly increase the response rate of acromegalic patients to SSA therapy. With its unique properties, Somatoprim has the potential to become the best-in-class somatostatin analog in a growing market that currently amounts to over 1.5 Billion US Dollars in annual sales.
Aspireo’s only investor is TVM Capital, a dedicated provider of equity capital to the international pharmaceutical, biopharmaceutical, medical technology and healthcare diagnostics industries. Aspireo is an Israeli company that was established in 2010 by TVM Capital as a Project Focused Company (PFC). Aspireo and the Somatoprim project are managed by a team of dedicated and experienced executives that are supported by a group of first-class collaborators/consultants with complementary and comprehensive knowledge and skills.